Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN101,7101,8-0,29
Msft0,42
Nokia4,624,6252,28
IBM1,15
Daimler AG47,10547,1153,34
PFE0,89
12.10.2019 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 11.10.2019 21:59:59
Roche Holding AG Depository Receipt (RHHBY.PK, US Other OTC (Pink Sheets))
Závěr k 10.10.2019 Změna (%) Změna (USD) Objem obchodů (ks)
35,99 0,44 0,16 5 567 221
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 13.10.2019
Popis společnosti
Obecné informace
Název společnostiRoche Holding Ltd. (ADR)
TickerRHHBY
Kmenové akcie:ADR
Kmenové akcie:Ordinary Shares
RICRHHBY.PK
ISINUS7711951043
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky30.06.2019
Počet zaměstnanců k 31.12.2018 94 442
Akcie v oběhu k 30.06.2019 854 428 000
MěnaCHF
Kontaktní informace
UliceGrenzacherstr. 124
MěstoBASEL
PSČ4058
ZeměSwitzerland
Kontatní osobaKarl Mahler
Funkce kontaktní osobyHead of Investor Relations
Telefon419 732 354 295
Kontatní telefon41 616 878 503

Business Summary: Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Financial Summary: BRIEF: For the six months ended 30 June 2019, Roche Holding Ltd. (ADR) revenues increased 8% to SF30.47B. Net income increased 18% to SF8.62B. Revenues reflect Roche Pharmaceuticals segment increase of 11% to SF22.21B, Chugai segment increase of 12% to SF1.99B, Diagnostics segment increase of less than 1% to SF6.28B. Net income benefited from Roche Pharmaceuticals segment income increase of 8% to SF9.42B, Chugai segment income increase of 34% to SF877M.
Odvětvová klasifikace
TRBC2012Pharmaceuticals - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYMajor Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSInVitro Diagnostic Substance Manufacturing
NAICSAnalytical Laboratory Instrument Manufacturing
NAICSSurgical Appliance and Supplies Manufacturing
NAICSSurgical and Medical Instrument Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSOffices of Other Holding Companies
SICPharmaceutical Preparations
SICBiological Prod's Not Diagnostic
SICDiagnostic Substances
SICAnalytical Instruments
SICSurgical Appliances And Supplies
SICSurgical And Medical Instruments
SICMedicinals And Botanicals
SICElectromedical Equipment
SICHolding Companies, Nec



  • Poslední aktualizace: 13.10.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive DirectorSeverin Schwan5201.01.2006
Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology OfficerAlan Hippe5201.04.201101.04.2011
Member of the Corporate Executive Committee, Head Group Human ResourcesCristina Wilbur52
Chief Compliance OfficerUrs Jaisli63
Member of the Corporate Executive Committee, General Counsel, Secretary to the Board of DirectorsGottlieb Keller6505.03.200801.01.1999
Member of the Corporate Executive Committee, Chief Executive Officer Roche PharmaceuticalsWilliam Anderson5201.01.201901.01.2019
Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED)William Pao5202.04.201802.04.2018
Member of the Enlarged Corporate Executive Committee, Global Head Pharma PartneringJames Sabry6001.08.201801.08.2018
Member of the Enlarged Corporate Executive Committee, Head Group CommunicationsBarbara Schaedler5701.10.201901.10.2019
Member of the Corporate Executive Committee, Chief Executive Officer Roche DiagnosticsThomas Schinecker4401.08.201901.08.2019